The impact of dupilumab treatment on SARS-CoV-2/COVID-19 antibody responses in atopic dermatitis patients

Immunomodulatory therapies are typically used to treat patients with moderate-to-severe atopic dermatitis (AD). Thus, it is critical to understand their effects on coronavirus disease 2019 (COVID-19) outcomes. We recently reported that patients with AD on dupilumab were more likely to be asymptomatic or have milder COVID-19 symptoms.1 However, the impact of dupilumab and systemic immunosuppressants on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 antibody levels in patients with AD remains unknown.